A Phase 1, Open-label Study in Healthy Participants to Investigate the Effect of Multiple-dose JNJ-56136379 on the Single-dose Pharmacokinetics of Bictegravir, Emtricitabine, and Tenofovir Alafenamide

The purpose of this study is to evaluate the effect of multiple-dose JNJ-56136379 on the single-dose pharmacokinetics (PK) of the combination of bictegravir (BIC), emtricitabine (FTC), tenofovir alafenamide (TAF) in healthy adult participants.

Start Date06 May 2021

Sponsor / Collaborator

Janssen Research & Development LLC

NCT04585789

/ CompletedPhase 2

A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing JNJ-73763989 and Nucleos(t)Ide Analog With or Without JNJ-56136379 in Patients With Chronic Hepatitis B Virus Infection

The purpose of this study is to assess changes in intrahepatic hepatitis B surface antigen (HBsAg) between baseline and on-treatment liver biopsy in response to JNJ-3989-based combination treatment.

Start Date11 Mar 2021

Sponsor / Collaborator

Janssen Research & Development LLC

NCT04439539

/ CompletedPhase 2

A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate Efficacy, Pharmacokinetics, Safety, and Tolerability of Treatment With JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog With or Without JNJ-56136379 in Treatment-naive Patients With HBeAg Positive Chronic Hepatitis B Virus Infection

The purpose of this study is to evaluate the efficacy of a treatment regimen of JNJ-73763989 + pegylated interferon alpha-2a (PegIFN-alpha-2a) + nucleos(t)ide analog (NA).

Start Date14 Sep 2020

Sponsor / Collaborator

Janssen Research & Development LLC

100 Clinical Results associated with Bersacapavir

100 Translational Medicine associated with Bersacapavir

100 Patents (Medical) associated with Bersacapavir

Literatures (Medical) associated with Bersacapavir

01 May 2026·GUT

Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT study

Article

Author: Chuang, Wan-Long ; Biermer, Michael ; Buti, Maria ; Jezorwski, John ; Klyashtornyy, Vladislav ; Verbinnen, Thierry ; Guinard-Azadian, Carine ; Lenz, Oliver ; Asselah, Tarik ; Kakuda, Thomas Naoki ; Kurosaki, Masayuki ; Kennedy, Patrick T F ; Fung, Scott ; Yilmaz, Gurdal

Background:

In the hepatitis B e antigen positive (HBeAg+) chronic infection disease phase, approved treatments have limited effects on hepatitis B surface antigen (HBsAg) and HBeAg.

Objective:

The phase 2 REEF-IT study ( NCT04439539 ) assessed safety, efficacy and pharmacokinetics of pegylated interferon-α2a (PegIFN-α2a) add-on to JNJ-73763989 (JNJ-3989)±bersacapavir+nucleos(t)ide analogues (NA) in not currently treated, HBeAg+chronic hepatitis B.

Design:

Participants received JNJ-3989 (200 mg every 4 weeks)+NA±bersacapavir (250 mg daily) for 36–52 weeks (induction) followed by 12 weeks of PegIFN-α2a (180 µg weekly) add-on. The primary endpoint was the proportion of participants with HBsAg seroclearance 24 weeks after stopping all treatment including NA. Changes in viral markers, safety and pharmacokinetics were assessed.

Results:

49/54 (91%) enrolled participants completed the study; 52% were male, with mean age of 33.6 years. No participant achieved the primary endpoint; one met NA completion criteria. 11/54 (20.4%) participants achieved HBsAg seroclearance at least once, 6 of them maintained it until Follow-up Week 48 (FUW48). Overall mean (SE) change from baseline in HBsAg of –2.85 (0.13), –3.61 (0.18) and –2.63 (0.26)log 10 IU/mL were observed at end of induction, end of treatment and FUW48. 16/53 (30.2%) participants reached HBeAg seroclearance at least once; 12 maintained it until FUW48. Similar proportions of participants experienced an adverse event (AE) during induction (83.3%), PegIFN-α2a add-on (85.7%) and follow-up (64.7%). There were no deaths or serious AEs; two participants discontinued PegIFN-α2a.

Conclusions:

In this population, adding PegIFN-α2a increased HBsAg declines after reductions by JNJ-3989; 20.4% achieved HBsAg seroclearance at least once. Treatment was generally safe with acceptable tolerability.

Trial registration number:

NCT04439539 .

01 Oct 2025·JHEP Reports

Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study

Article

Author: Thierry Verbinnen ; Michael Biermer ; Wan-Long Chuang ; Ting-Tsung Chang ; Yasuhiro Asahina ; Ewa Janczewska ; Adam Bakala ; Cheng-Yuan Peng ; Zacharias Anastasiou ; Ronald Kalmeijer ; Nonko Pehlivanov ; Edward Gane ; Gloria Kim ; Maria Hlebowicz ; Oliver Lenz ; Thomas N. Kakuda ; Tetsuo Takehara ; John Jezorwski

Background & Aims:

Previous studies showed that combination treatment with short interfering RNA JNJ-73763989 (JNJ-3989) ± capsid assembly modulator bersacapavir (JNJ-56136379) and nucleos(t)ide analogs (NAs) was well tolerated by patients with chronic HBV (CHB), with JNJ-3989 dose-dependent reductions in viral markers, including HBsAg. The open-label, single-arm phase IIa PENGUIN study (NCT04667104) evaluated this regimen plus pegylated interferon alpha-2a (PegIFN-α2a) in patients with virologically suppressed CHB.

Methods:

Patients who were either HBeAg-positive or -negative virologically suppressed and taking NAs were included; all received JNJ-3989 ± bersacapavir for 24 weeks (some either did not start or discontinued bersacapavir as a result of protocol amendment) with PegIFN-α2a added during the final 12 weeks of treatment. The primary endpoint was the proportion of patients with ≥2 log₁₀ IU/ml HBsAg reduction from baseline at week 24 (W24). Safety, tolerability, and proportion of patients meeting predefined NA stopping criteria were assessed. After 24 weeks of treatment, NA was stopped when stopping criteria were met; all patients were followed for 48 weeks. Efficacy and safety endpoints were summarized using descriptive statistics.

Results:

In total, 48 patients (HBeAg positive, n = 11; HBeAg negative, n = 37) were enrolled; 47 reached follow-up week 48 (FUW48). Of the 48 patients, 31 (64.6%) achieved the primary endpoint; one achieved HBsAg seroclearance (<0.05 IU/ml) at both W24 and FUW48 after stopping NA. Mean HBsAg changes from baseline were -1.43, -2.18, and -0.71 log₁₀IU/ml at W12, W24, and FUW48, respectively. At W24, 15/48 (31.3%) patients met NA stopping criteria; 11/15 (73.3%) remained off NA by FUW48. One patient achieved functional cure at FUW48. Adverse events were consistent with known PegIFN-α2a safety profiles.

Conclusions:

Treatment with JNJ-3989 ± bersacapavir + NA and PegIFN-α2a was generally well tolerated. Most patients had pronounced HBsAg reductions from baseline, no additional benefit from PegIFN-α2a, and did not achieve functional cure.

Clinical Trials registration:

The study is registered at ClinicalTrials.gov (NCT04667104).

Impact and implications:

Previous studies with JNJ-73763989 (JNJ-3989) ± bersacapavir (JNJ-56136379) and nucleos(t)ide analogs (NAs) in patients with chronic hepatitis B (CHB) have demonstrated JNJ-3989 dose-dependent and robust reductions in viral markers; however, functional cure was only rarely achieved. The current study assessed whether the addition of pegylated interferon alpha-2a (PegIFN-α2a) to a JNJ-3989-based regimen after HBsAg levels were reduced would lead to further HBsAg declines and improved outcomes during off-treatment follow-up. Study results confirmed pronounced HBsAg reductions from baseline in virologically suppressed patients with HBeAg-positive or -negative CHB. However, the addition of PegIFN-α2a to JNJ-3989 ± bersacapavir and NA for the final 12 weeks of a 24-week treatment period did not appear to improve antiviral activity in the studied population. Studies in other CHB groups, including treatment-naïve, HBeAg-positive patients, could help elucidate whether this or other treatment regimens including JNJ-3989 and NA can lead to functional cure in a larger proportion of patients.

01 Jan 2025·JOURNAL OF PHARMACEUTICAL SCIENCES

Synchrotron computed tomography combined with AI-based image analysis for the advanced characterization of spray dried amorphous solid dispersion particles

Article

Author: Marcozzi, Tatiana ; Baviriseaty, Sruthika ; Vanhoorne, Valérie ; Vervaet, Chris ; Zhang, Shawn ; Andersen, Sune Klint ; Yawman, Phillip

Particle engineering aims to design particles with specific properties. A deeper understanding of how particle formation relates to material attributes and process conditions are critical to strengthen knowledge on powder properties and enhance modeling capabilities. New, alternative powder characterization techniques can offer novel and more accurate measures for particle properties, giving more advanced characterization information. In this context, a case study is presented in which spray dried amorphous solid dispersion powders produced by modifying process conditions were characterized by both well-established compendial methods (i.e., laser light diffraction, SEM image analysis, bulk and tapped density, and gas adsorption), as well as a new method combining synchrotron computed tomography (SyncCT) with AI-based image analysis. SyncCT was used to classify and quantify the spray dried particles as hollow spheres and solid particles, giving a more detailed quality measure of the particle shape, as they impact downstream processing differently. Moreover, hollow particle wall thicknesses, as well as internal and external particle surface areas were measured by SyncCT. Altogether, powder characterization data from SyncCT show similar trends to that obtained from compendial techniques and giving additional quality measure regarding particle shape, showing promise of this new and advanced characterization method.

News (Medical) associated with Bersacapavir

07 Jun 2022

·www.biospace.com

Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences

June 7, 2022 11:30 UTC PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Healthcare Conference – June 8-10, 2022 Type: Fireside chat presentation Presenter: Vincent Anzalone, Vice President Finance and Investor Relations, Arrowhead Pharmaceuticals Goldman Sachs 43rd Annual Global Healthcare Conference – June 13-16, 2022 Type: Fireside chat presentation Presenter: Vincent Anzalone, Vice President Finance and Investor Relations, Arrowhead Pharmaceuticals The International Liver Congress™ 2022 - The Annual Meeting of the European Association for the Study of the Liver (EASL) – June 22-26, 2022 Title: Effects of the siRNA JNJ-3989 and/or the Capsid Assembly Modulator JNJ-6379 on Viral Markers of Chronic Hepatitis B: Results From the REEF-1 Study Presenter: Man-Fung Yuen, Department of Medicine & State Key Laboratory of Liver Research, Queen Mary Hospital, The University of Hong Kong Title: Understanding the Dynamics of HBsAg Decline Through Model-informed Drug Development (MIDD) of siRNA and CAM-N for the Treatment of Chronic Hepatitis B (CHB) Virus Infection Presenter: Huybrecht T’jollyn, Janssen Research & Development Title: Efficacy and Safety of Finite 48-week Treatment With the siRNA JNJ-3989 and the Capsid Assembly Modulator JNJ-6379 in HBeAg Negative Virologically Suppressed Chronic Hepatitis B Patients: Results from the REEF-2 Study Presenter: Kosh Agarwal, Institute of Liver Studies, King’s College Hospital Title: Reduction of Intra-hepatic Z-AAT Synthesis by Fazirsiran Decreases Globule Burden and Improves Histological Measures of Liver Disease in Adults with Alpha-1 Antitrypsin Deficiency Presenter: Pavel Strnad, Department of Internal Medicine III, University Hospital, Rwth Aachen A copy of the presentation materials and webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit , or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit . Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” or “continue” are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc.

CollaboratesiRNA

09 Apr 2021

·www.globenewswire.com

Hepatitis B Virus Infection - Global Drug Forecast and Market Analysis to 2029

New York, April 09, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Hepatitis B Virus Infection - Global Drug Forecast and Market Analysis to 2029" - For most patients, CHB is a lifelong disease that cannot be cured, with only a very small number of patients entering remission each year.Patients with CHB have a 20% risk of developing life-threatening liver disease, such as cirrhosis and hepatocellular carcinoma (HCC) as a result of their condition.Guidelines by the American Association of the Study of Liver Diseases (AASLD) and the European Association for the Study of Liver (EASL) have recommended CHB to be treated with nucleotide analogs (NA).Gilead Sciences and Bristol Myers Squibb (BMS) are the major players within the CHB market with their nucleotide analogs Viread (TDF, Gilead), Vemlidy (TAF, Gilead) and Baraclude (entecavir, BMS).However, generic versions of TDF and entecavir dominate the 9MM.The CHB treatment pipeline is predominantly in early stages.Gilead’s TLR-8 agonist selgantolimod, J&J’s capsid assembly modulator JNJ-6379, and antisense nucleotide JNJ-3898 could significantly impact the CHB market across the 9MM.Also Replicor, Assembly Biosciences, and Ionis Pharmaceuticals are developing CHB therapies. A major unmet for CHB treatment remains the potential to achieve functional cure.Key Highlights- During the 10-year forecast period, there are six major pipeline products that are on track to launch, driving a forecast growth in the 9MM from $3.8B in 2019 to $5.2B in 2029, which represents a CAGR of 3.1%.- To combat the unmet need of a functional cure, companies such as Gilead, J&J, Replicor, Ionis, and Assembly Biosciences are developing pipeline products with novel mechanism of action, with the potential of being used as a combination therapy either with current nucleotide analogs or with emerging products.- The pipeline products are expected to launch in the second half of the forecast period in 2029. Antisense nucleotides are expected to gain a market share of 14.7% and sales of $761M in the 9MM by 2029. However, capsid assembly modulators from J&J and a toll-like receptor 8 agonist from Gilead are expected to compete with antisense nucleotides for market shares in the 9MM by the end of the forecast period.Key Questions Answered- How will the CHB market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) change from 2019-2029?- What are the most promising late-stage pipeline products for CHB treatment?- How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing CHB treatment options?- What are the remaining unmet needs in CHB treatment?- What drivers and barriers will affect CHB treatment sales in the 9MM over the forecast period?Scope- Overview of CHB, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.- Topline CHB treatment market revenue from 2019-2029. Annual cost of therapy and major pipeline product sales in this forecast period are included.- Key topics covered include current CHB treatment, unmet needs and opportunities, and the drivers and barriers affecting CHB treatment sales in the 9MM.- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.- Analysis of the current and future market competition in the global CHB treatment market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.Reasons to BuyThe report will enable you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global Hepatitis B Virus Infection market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Hepatitis B Virus Infection market in the future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.Read the full report: ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________

100 Deals associated with Bersacapavir

External Link

KEGG	Wiki	ATC	Drug Bank
D12126	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis B, Chronic	Phase 2	United States	Xian-Janssen Pharmaceutical Ltd.	13 Feb 2018
Hepatitis B, Chronic	Phase 2	United States	Janssen Research & Development LLC	13 Feb 2018
Hepatitis B, Chronic	Phase 2	United States	Janssen Sciences Ireland Unlimited Co.	13 Feb 2018
Hepatitis B, Chronic	Phase 2	China	Janssen Sciences Ireland Unlimited Co.	13 Feb 2018
Hepatitis B, Chronic	Phase 2	Japan	Janssen Sciences Ireland Unlimited Co.	13 Feb 2018
Hepatitis B, Chronic	Phase 2	Japan	Janssen Research & Development LLC	13 Feb 2018
Hepatitis B, Chronic	Phase 2	Japan	Xian-Janssen Pharmaceutical Ltd.	13 Feb 2018
Hepatitis B, Chronic	Phase 2	Belgium	Janssen Sciences Ireland Unlimited Co.	13 Feb 2018
Hepatitis B, Chronic	Phase 2	Belgium	Xian-Janssen Pharmaceutical Ltd.	13 Feb 2018
Hepatitis B, Chronic	Phase 2	Belgium	Janssen Research & Development LLC	13 Feb 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04129554 (REEF-2, CTgov)	Phase 2	Hepatitis B, Chronic	130	JNJ-73763989+JNJ-56136379 (Arm 1: JNJ-73763989 (200 Milligrams [mg])+JNJ-56136379 (250 mg)+NA)	vkzfwvobwt = ppafnrxzqx dqlzadeywr (iulmnxdrwg, dmlzagugbm - cszviccxfd) View more	-	31 Jul 2024
				Nucleos(t)Ide Analog (Arm 2: Nucleos(t)Ide Analog (NA))	vkzfwvobwt = hcmqqgtntb dqlzadeywr (iulmnxdrwg, paznquntuu - tyisbqqacf) View more
NCT04129554 (REEF-2, Pubmed) Manual	Phase 2	Hepatitis B, Chronic Hepatitis B e-antigen (HBeAg)-negative \| HBsAg	130	JNJ-73763989-6JNJ-56136379	kkpfiophhj(jgzqmlntyp) = nzewgsamtb dowgfytgys (ayxqmsjtao ) View more	Negative	05 Apr 2024
				Placebos for JNJ-3989 and JNJ-6379 + active NA	kkpfiophhj(jgzqmlntyp) = rosqrrcgkl dowgfytgys (ayxqmsjtao ) View more
NCT04585789 (INSIGHT, CTgov)	Phase 2	Hepatitis B, Chronic	24	NA+TAF+JNJ-3989+PegIFN-alpha-2a+JNJ-6379+ETV (Panel 1)	zzfemntens(ipodiqjlvv) = qhjaskabhc smijigkcxc (sziuncqxee, vxztxaegoy - qpywhjwmjg) View more	-	05 Mar 2024
				PegIN-alpha2a+TAF+JNJ-3989+PegIFN-alpha-2a+JNJ-6379+ETV (Panel 2)	zzfemntens(ipodiqjlvv) = wjlwsvvxrt smijigkcxc (sziuncqxee, umfnbqxqzh - mftuveqkwb) View more
NCT03982186 (REEF-1, Pubmed) Manual	Phase 2	Hepatitis B, Chronic First line	470	JNJ-6379+JNJ-3989 (JNJ-3989 dual 40 mg group)	qdgfewdyka(kgzleamlyk) = oemkrtvzfw sqkeigyfcy (gjgkqzcfnt, 2 - 11)	Positive	10 Jul 2023
				JNJ-6379+JNJ-3989 (JNJ-3989 dual 100 mg group)	qdgfewdyka(kgzleamlyk) = cpkkoakpka sqkeigyfcy (gjgkqzcfnt, 10 - 24)
NCT03361956 (JADE, Pubmed)	Phase 2	Hepatitis B, Chronic	232	JNJ-56136379 75 mg+NA	gmfvprvjrn(lowwypclbm) = csziklswfe ppmybzwjjy (fkngpadwnt ) View more	Positive	25 Jan 2023
				JNJ-56136379 250 mg+NA	gmfvprvjrn(lowwypclbm) = anwbavdxmu ppmybzwjjy (fkngpadwnt ) View more
NCT04129554 (REEF-2, Corporate Publications) Manual	Phase 2	Hepatitis B, Chronic HBeAg Negative	130	ETV/TDF/TAF+JNJ 73763989+JNJ 56136379	yldwvqiqjp(efhwnqtvqc) = pxuzmtbxsa bfnwpiacar (fsxfmdcxuk ) View more	Negative	27 Jun 2022
				ETV/TDF/TAF+Placebo+Placebo	yldwvqiqjp(efhwnqtvqc) = gipjqpxhsh bfnwpiacar (fsxfmdcxuk ) View more
NCT03982186 (REEF-1, EASL2022)	Phase 2	Hepatitis B, Chronic HBeAg+ \| HBeAg-	470	JNJ-3989 100 mg	uongxlwyag(pkxpwlnbaw) = iealvyydif inbqfnukwi (neknamrkge )	-	25 Jun 2022
				JNJ-3989 200 mg	uongxlwyag(pkxpwlnbaw) = zqgsjnkpkw inbqfnukwi (neknamrkge ) View more
NCT04129554 (REEF-2, EASL2022)	Phase 2	Hepatitis B, Chronic Add-on	130	JNJ-3989 200 mg SC Q4W	iwjwrybmfp(srvrnkzxjq) = wynweeudpv jhkbwohisc (lriopdfwib ) View more	Positive	24 Jun 2022
				Placebo	iwjwrybmfp(srvrnkzxjq) = irwphbratd jhkbwohisc (lriopdfwib ) View more
NCT02662712 (EASL2019)	Phase 2	Hepatitis B, Chronic	57	JNJ-6379 75 mg	oosyepohja(mqmvryvdvp) = yethsfmuln recxormvpc (alolxjmqrc )	-	12 Apr 2019
NCT02662712 (EASL2019)	Phase 1	Hepatitis B, Chronic HBcrAg \| HBeAg-positive \| HBsAg	57	JNJ-6379 25 mg	zklttyerdo(nqzyealsdb) = teuwtsobly iapdtnnzdw (meatzyrads, 1.3)	-	12 Apr 2019
				JNJ-6379 75 mg	zklttyerdo(nqzyealsdb) = hzxtlxgpch iapdtnnzdw (meatzyrads, 1.5)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis